Rapid induction of hepatocyte growth factor by heparin

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

ESMO open·2024

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

ESMO open·2024

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Lancet (London, England)·2026

Robotic-arm-assisted versus conventional total knee replacement (RACER-Knee): a pragmatic, multicentre, participant-masked and assessor-masked, superiority, randomised controlled trial.

Lancet (London, England)·2026

Risk of transmission of amyloid β pathology via transfused blood products.

Lancet (London, England)·2026

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Lancet (London, England)·2026

CpG content contributes to tissue-resident macrophage enhancer selection.

Nucleic acids research·2026

Transferrin Promotes Oligodendroglial Differentiation Independently of Iron Binding and Release.

ASN neuro·2026

Shear wave elastography of dermal stiffness after radiofrequency ablation for great saphenous vein reflux: A 12-month prospective study.

Phlebology·2026

Regenerative wound healing enabled by recombinant humanized collagen III releasing composite hydrogel.

Acta biomaterialia·2026

Tissue engineering scaffolds for the spinal cord: recent advances and future prospects.

Journal of biomaterials science. Polymer edition·2026

The Efficacy of Transosseous Foveal Repair Combined With Dorsal Reinforcement in the Treatment of Chronic Triangular Fibrocartilage Complex Injury With Severe Distal Radioulnar Joint Instability.

The Journal of hand surgery·2026

Related Experiment Videos

Rapid induction of hepatocyte growth factor by heparin

Related Concept Videos

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Robotic-arm-assisted versus conventional total knee replacement (RACER-Knee): a pragmatic, multicentre, participant-masked and assessor-masked, superiority, randomised controlled trial.

Risk of transmission of amyloid β pathology via transfused blood products.

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

CpG content contributes to tissue-resident macrophage enhancer selection.

Transferrin Promotes Oligodendroglial Differentiation Independently of Iron Binding and Release.

Shear wave elastography of dermal stiffness after radiofrequency ablation for great saphenous vein reflux: A 12-month prospective study.

Regenerative wound healing enabled by recombinant humanized collagen III releasing composite hydrogel.

Tissue engineering scaffolds for the spinal cord: recent advances and future prospects.

The Efficacy of Transosseous Foveal Repair Combined With Dorsal Reinforcement in the Treatment of Chronic Triangular Fibrocartilage Complex Injury With Severe Distal Radioulnar Joint Instability.

Related Experiment Videos

Rapid induction of hepatocyte growth factor by heparin

Related Concept Videos

Related Articles